SCHEMBL2378017

SCHEMBL2378017

CN1CCN(C(=O)c2ccc(CCNC(=O)OC(C)(C)C)cc2)CC1

nearest known ligand 0.55

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
NAMPT P43490 1/20 0.55
HPGD P15428 2/20 0.51
ALOX15 P16050 1/20 0.51
SIGMAR1 Q99720 3/20 0.51
HRH3 Q9Y5N1 2/20 0.49
CA1 P00915 1/20 0.48
CA2 P00918 1/20 0.48
CNR2 P34972 1/20 0.48
ALDH1A1 P00352 2/20 0.47
POLB P06746 3/20 0.47
KDM4E B2RXH2 1/20 0.46
DRD2 P14416 1/20 0.46
NPC1 O15118 1/20 0.45
LMNA P02545 1/20 0.45
SMN1; SMN2 Q16637 1/20 0.45
CHKA P35790 1/20 0.45
MEN1 O00255 1/20 0.44
KMT2A Q03164 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2378092 0.88 NAMPT (0.54) NAMPTHPGDALOX15HRH3CNR2
SCHEMBL23291239 0.83 NAMPT (0.55) NAMPTSIGMAR1CA1CA2CNR2
SCHEMBL20897600 0.81 KMT2A (0.56) ALDH1A1POLBKDM4ENPC1LMNA
SCHEMBL2378879 0.79 HRH3 (0.58) HPGDALOX15HRH3ALDH1A1POLB
SCHEMBL3400767 0.79 EPHX2 (0.60) NAMPTHPGDALOX15POLBKDM4E
SCHEMBL23928164 0.78 SIGMAR1 (0.51) NAMPTSIGMAR1HRH3CA1CA2
SCHEMBL379892 0.78 CA2 (0.54) NAMPTSIGMAR1CA1CA2ALDH1A1
SCHEMBL3868210 0.78 CA2 (0.54) NAMPTCA1CA2ALDH1A1KDM4E
SCHEMBL23828891 0.78 NAMPT (0.57) NAMPT
SCHEMBL30453424 0.78 NAMPT (0.57) NAMPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2050749-B1 PYRIMIDINE DERIVATIVE AS PI3K INHIBITOR AND USE THEREOF CHUGAI PHARMACEUTICAL CO LTD (JP) 2017-11-22 EP disclosed
US-8022205-B2 Pyrimidine derivatives as PI3K inhibitor and use thereof CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2011-09-20 US disclosed
US-20100069629-A1 PYRIMIDINE DERIVATIVES AS PI3K INHIBITOR AND USE THEREOF CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2010-03-18 US disclosed
EP-2050749-A1 PYRIMIDINE DERIVATIVE AS PI3K INHIBITOR AND USE THEREOF CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2009-04-22 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100069629-A1 PYRIMIDINE DERIVATIVES AS PI3K INHIBITOR AND USE THEREOF PIK3CA, AKT3, AKT1 NAMPT 233/4885HPGD 1383/4885ALOX15 3901/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.